Perle Bioscience, Inc. is investigating a novel combination therapy for Type 1 Diabetes Mellitus that leverages two FDA-approved drugs, Cyclosporine A and Lansoprazole, to potentially achieve insulin independence in patients. The market for Type 1 Diabetes therapies is significant, with a growing demand for innovative treatments that can improve patient outcomes. The competitive landscape includes existing therapies that focus on insulin management rather than addressing the underlying autoimmune mechanisms. The withdrawal of this trial prior to patient enrollment raises concerns about the feasibility of the study design or potential regulatory hurdles, which may necessitate further diligence regarding the clinical and commercial viability of this approach.